1) Arai N, Kagami H, Mine Y, Ishii T, Inaba M:Primary solitary intracranial malignant melanoma:a systematic review of literature. World Neurosurg 117:386-393, 2018
2) Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA;BRIM-3 Study Group:Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
3) Glitza Oliva IC, Schvartsman G, Tawbi H:Advances in the systemic treatment of melanoma brain metastases. Ann Oncol 29:1509-1520, 2018
4) Li CB, Song LR, Li D, Weng JC, Zhang LW, Zhang JT, Wu Z:Primary intracranial malignant melanoma:proposed treatment protocol and overall survival in a single-institution series of 15 cases combined with 100 cases from literature. J Neurosurg 132:902-913, 2019
5) Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A;KEYNOTE-006 investigators:Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
6) Tang K, Kong X, Mao G, Qiu M, Zhu H, Zhou L, Nie Q, Xu Y, Du S:Primary cerebral malignant melanoma:a case report with literature review. Medicine(Baltimore)96:e5805, 2017